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patients with persistent asthma and chronic obstructive pulmonary disease 
(COPD) in the United Kingdom (UK). The potential cost benefit of improved inha-
lation technique, due to the innovative characteristics of the Spiromax® inhaler, 
was also investigated. Methods: The eligible adult patient population was 
based on current confirmed UK asthma and COPD diagnosis rates, with the pro-
portion of patients receiving FDCs based on market research data. The costs of 
Symbicort® Turbohaler® and scheduled and unscheduled health care events were 
taken from publically available UK sources. Frequency of poor inhalation tech-
nique with Symbicort® Turbohaler® and the associated increased risk of unsched-
uled health care events were taken from a large (n= 1,664) cross-sectional, Italian 
observational study. The estimated reduction in the proportion of patients with 
poor inhalation technique with DuoResp® Spiromax® compared with Symbicort® 
Turbohaler® was based on a conservative assumption. Results: An estimated 
409,445 adult patients used Symbicort® Turbohaler® annually in the UK and 
were therefore eligible for treatment with DuoResp® Spiromax®, with 178,108 of 
these exhibiting poor inhalation technique. Assuming a hypothetical uptake of 
DuoResp® Spiromax® reaching 25% in year 4 and 5 and its anticipated price, 
the model predicted drug cost savings totalling £36.09 million. Furthermore, 
39,266 unscheduled health care events could be avoided due to the predicted 
improvement in inhalation technique with DuoResp® Spiromax® com-
pared with Symbicort® Turbohaler®, resulting in further savings of £3.50 mil-
lion. ConClusions: DuoResp® Spiromax® is likely to offer budgetary savings 
compared with Symbicort® Turbohaler®, with further cost savings potentially 
resulting from improved inhalation technique.
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objeCtives: Chronic obstructive pulmonary disease (COPD) is an obstructive 
lung disease characterized by persistent airflow limitation. COPD has a signifi-
cant humanistic burden, representing the 5th leading cause of death in Portugal. 
The prevalence of Portuguese population with more than 40 years is 14.2%. COPD 
symptoms are similar to other respiratory diseases, making harder its diagnosis. 
Furthermore, it may result in inappropriate use of medication which is associated 
with an economic burden. This analysis aimed to estimate the economic impact 
of inappropriate use of inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) 
fixed-dosed combination in COPD patients. Methods: GOLD 2013 treatment algo-
rithm establish that ICS therapy should only be considered in high risk population 
(patients classified within GOLD groups C and D), presenting FEV1 < 50% (forced 
expiratory volume at 1 second) and/or 2 or more exacerbations per year. Based on 
a Delphi panel there are 1% of patients in group C and 29% in group D. According 
to ECLIPSE study, only 31% of patients in group C and 37% in group D are illegible 
for ICS therapy. Based on these assumptions, we estimated the overtreatment of 
ICS/LABA in Portugal according with local COPD prevalence and number of ICS/
LABA fixed-dosed combinations prescribed. It was also calculated the economic 
impact associated with therapy switch of over treated patients from ICS/LABA to 
glycopyrronium or indacaterol, according to GOLD 2013. Results: The treatment 
with ICS/LABA was estimated to be approximately 1.6 times greater than expected. 
Considering the number of patients over treated with ICS/LABA, the therapy switch 
for indacaterol or glycopyrronium would result in a potential saving of 4,314,390€ 
or 8,694,008€ , respectively. ConClusions: Optimization of COPD therapy in com-
pliance with GOLD guidelines would result in a better treatment for patients and 
potential savings, in a Portuguese National Health Service perspective.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease 
with a significant economic burden to the UK National Health Service (NHS). NICE 
recommends maintenance treatment including inhaled bronchodilator medica-
tions such as long-acting muscarinic antagonists (LAMAs); tiotropium is the 
most widely used LAMA in the UK. The objective of this model was to quantify 
the budget impact to the NHS of switching patients from tiotropium to another 
LAMA, compared to remaining on tiotropium. Methods: Two matched patient 
groups were considered: patients who switched from tiotropium to another LAMA 
and patients who remained on tiotropium. The budget impact model was con-
ducted over a 3 month time horizon, with sensitivity analyses conducted over a 
12 month time horizon. Costs included were costs of medication; costs of patient 
identification and new inhaler training; and primary care resource use in the 
3 months following inhaler switch, priced according to PSSRU estimates. The 
number and duration of GP visits was estimated from the CPRD; a representative 
primary care patient database. Clinical efficacy endpoints were not included in 
the model. Results: Across the 3 month time horizon, patients who switched 
therapy incurred an increased incremental cost to the NHS of £77.10 per patient 
compared to patients who remained on tiotropium. Switching from tiotropium 
to other LAMA therapy also increased the NHS economic burden in the 12 month 
sensitivity analyses. Increased costs were driven by higher resource utilisation in 
terms of GP visits amongst switchers. ConClusions: Switching patients with 
COPD from tiotropium maintenance to another LAMA incurs an increased cost 
to the NHS. This is primarily due to a higher primary care resource use in the 3 
months following switch. This finding has implications for prescribing practice 
including GP workload and patient willingness to switch, hence patients remaining 
on tiotropium are cost-saving for the UK NHS
COPD cost was 3,290.7 [95%CI: 2539.9; 4051.2], but € 1161.0 [95% CI: 968.4; 1,353.6] 
in survivors and 6,158.9 [95% CI: 5,508.0; 6,809.8] in those who died, respectively 
(p< 0.001). The hospitalization cost impacted for 78.2% of the total annual cost in 
subjects who died, the absolute value being sixfold higher than in survivors. All 
economic components of cost were discriminant at three years, independently of 
gender. ConClusions: 1) several clinical and lung function variables contribute to 
predict mortality in COPD; 2) identification of COPD phenotypes is crucial, but mul-
tiple indices are required; 3) total annual cost proved the most sensitive predictor 
of mortality at three years; 4) annual cost is much easier and cheaper to obtain over 
twelve months; 5) data are supporting the high predicting value and the conveni-
ence of COPD “economic phenotyping”.
ReSPiRaToRy-RelaTeD DiSoRDeRS – cost Studies
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objeCtives: Fluticasone furoate/vilanterol (FF/VI) 92/22 mcg is a once-daily, fixed-
dose combination inhaled corticosteroid + bronchodilator licensed for the treatment 
of COPD in the UK. A budget impact model (BIM) was designed to explore the cost 
implications of prescribing FF/VI 92/22 in adult patients who continue to exacerbate 
or are currently receiving an off-license therapy versus alternative ICS/LABA thera-
pies, in line with clinical guidelines. Methods: A one-year BIM was constructed to 
explore the financial outcomes of prescribing FF/VI 92/22 as an alternative treatment 
option to currently prescribed therapies based on market shares. The BIM is based 
on UK prescription analysis, epidemiological and resource data. The model explores 
three routes for progressing patients: 1) exacerbating patients currently on LAMA or 
LABA monotherapy progressing onto ICS/LABA combination therapy; 2) exacerbat-
ing patients currently on ICS/LABA combination therapy progressing onto triple 
therapy; 3) patients currently on off-license therapies moved onto licensed COPD 
products. The model does not explore differences in patient outcomes, efficacy or 
safety; it explores drug acquisition cost alone. Results: The BIM estimates that 
the average health economy (e. g. clinical commissioning group; local health board) 
in the UK has 3066 COPD patients of whom 2138 continue to exacerbate or are 
prescribed off licence therapies. In year 1, progressing exacerbating patients onto 
alternative ICS/LABA combinations or triple therapy (50% implementation rate), or 
patients on off-license therapies onto licensed therapies (100% implementation rate) 
results in a budget impact of £156,498 compared with a budget impact of -£51,907 
if these patients are moved onto FF/VI 92/22. ConClusions: The introduction of 
FF/VI 92/22 in COPD has the potential to reduce the budget impact and total spend 
on combination ICS/LABA therapies by £208,405 in the average UK health economy 
compared to current patterns of prescribing.
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objeCtives: Fluticasone furoate/vilanterol (FF/VI) is a once-daily, fixed-dose combi-
nation inhaled corticosteroid + bronchodilator licensed for the treatment of asthma 
in the UK. A budget impact model (BIM) was designed to explore the cost implica-
tions of initiating FF/VI in patients ≥ 12 years not adequately controlled on ICS 
monotherapy (and as needed SABA) versus alternative ICS/LABA therapies, in line 
with BTS-SIGN guidelines. Methods: A one-year BIM was constructed to explore 
the financial outcomes of prescribing FF/VI as a treatment option in these dynamic 
patients. The BIM is based on UK epidemiological and resource data. It compares a 
scenario in which all eligible patients are treated with currently available ICS/LABA 
products based on market shares with a scenario in which FF/VI is introduced for 
uncontrolled patients eligible for step up onto an ICS/LABA combination therapy 
in line with clinical guidelines. The model does not explore differences in patient 
outcomes, efficacy or safety; it explores drug acquisition cost alone. Results: The 
BIM estimates that the average health economy (e. g. clinical commissioning group; 
local health board) in the UK has 7326 patient on ICS monotherapy of whom 3736 
are inadequately controlled and appropriate for step-up to an ICS/LABA combina-
tion therapy. In year 1, presuming a 50% implementation rate, stepping up these 
patients onto alternative ICS/LABA combinations at current usage rates results in 
a budget impact of £342,413 compared with a budget impact of £313,167 if these 
patients initiate FF/VI therapy. ConClusions: The introduction of FF/VI in asthma 
has the potential to reduce the budget impact and total spend on combination ICS/
LABA therapies by £29,246 in the average UK health economy compared to current 
patterns of prescribing.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting 
beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was 
developed to assess the budget impact of using DuoResp® Spiromax® instead 
of Symbicort® Turbohaler® – a DPI delivering the same FDC – to manage adult 
